These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30825614)

  • 1. Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours.
    Knight JC; Mosley MJ; Kersemans V; Dias GM; Allen PD; Smart S; Cornelissen B
    Nucl Med Biol; 2019 Mar; 70():14-22. PubMed ID: 30825614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor uptake and tumor/blood ratios for [
    Al-Saden N; Cai Z; Reilly RM
    Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
    Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
    J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
    Razumienko E; Dryden L; Scollard D; Reilly RM
    Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B.
    Ma MT; Meszaros LK; Paterson BM; Berry DJ; Cooper MS; Ma Y; Hider RC; Blower PJ
    Dalton Trans; 2015 Mar; 44(11):4884-900. PubMed ID: 25351250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
    Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE
    Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
    Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
    Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
    Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
    Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
    Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
    [No Abstract]   [Full Text] [Related]  

  • 17. [
    Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabelling and preclinical characterisation of [
    Cao Z; Wichmann CW; Burvenich IJG; Osellame LD; Guo N; Rigopoulos A; O'Keefe GJ; Scott FE; Lorensuhewa N; Lynch KP; Scott AM
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3202-3214. PubMed ID: 38730087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo PET Imaging of
    Pham TT; Chenoweth A; Patel N; Banu A; Osborn G; Blower PJ; Karagiannis SN; Ma MT
    J Nucl Med; 2024 Jul; 65(7):1035-1042. PubMed ID: 38844362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.